NL8700191A - Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen. - Google Patents

Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen. Download PDF

Info

Publication number: NL8700191A
Authority: NL; Netherlands
Prior art keywords: compound; immunosuppressive; compounds; day; quinoline
Prior art date: 1986-01-31

Application number

NL8700191A

Other languages

English (en)

Dutch (nl)

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-01-31

Filing date

1987-01-27

Publication date

1987-08-17

1987-01-27 Application filed by Sandoz Ag filed Critical Sandoz Ag

1987-08-17 Publication of NL8700191A publication Critical patent/NL8700191A/nl

Links

239000003018 immunosuppressive agent Substances 0.000 title claims description 28
229940125721 immunosuppressive agent Drugs 0.000 title claims description 28
239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
239000003795 chemical substances by application Substances 0.000 title description 4
238000011282 treatment Methods 0.000 claims description 33
230000000694 effects Effects 0.000 claims description 29
230000001506 immunosuppresive effect Effects 0.000 claims description 28
229910052757 nitrogen Inorganic materials 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
-1 N-diethylsulfamoylamino Chemical group 0.000 claims description 7
206010003246 arthritis Diseases 0.000 claims description 7
238000011260 co-administration Methods 0.000 claims description 6
201000004681 Psoriasis Diseases 0.000 claims description 4
238000002650 immunosuppressive therapy Methods 0.000 claims description 3
201000006417 multiple sclerosis Diseases 0.000 claims description 3
AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 claims description 2
208000032467 Aplastic anaemia Diseases 0.000 claims description 2
206010007134 Candida infections Diseases 0.000 claims description 2
208000002691 Choroiditis Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
208000003084 Graves Ophthalmopathy Diseases 0.000 claims description 2
208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
208000007027 Oral Candidiasis Diseases 0.000 claims description 2
208000003971 Posterior uveitis Diseases 0.000 claims description 2
201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
241000287411 Turdidae Species 0.000 claims description 2
208000007502 anemia Diseases 0.000 claims description 2
201000003984 candidiasis Diseases 0.000 claims description 2
201000001981 dermatomyositis Diseases 0.000 claims description 2
239000000203 mixture Substances 0.000 claims description 2
206010028417 myasthenia gravis Diseases 0.000 claims description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 12
239000008194 pharmaceutical composition Substances 0.000 claims 4
206010008909 Chronic Hepatitis Diseases 0.000 claims 1
206010016654 Fibrosis Diseases 0.000 claims 1
206010019755 Hepatitis chronic active Diseases 0.000 claims 1
230000007882 cirrhosis Effects 0.000 claims 1
208000019425 cirrhosis of liver Diseases 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
RHGUXDUPXYFCTE-ZWNOBZJWSA-N ergoline Chemical compound C1=CC([C@@H]2[C@H](NCCC2)C2)=C3C2=CNC3=C1 RHGUXDUPXYFCTE-ZWNOBZJWSA-N 0.000 claims 1
201000000306 sarcoidosis Diseases 0.000 claims 1
201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
206010043554 thrombocytopenia Diseases 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 89
229930182912 cyclosporin Natural products 0.000 description 56
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 47
108010036949 Cyclosporine Proteins 0.000 description 47
229960001265 ciclosporin Drugs 0.000 description 47
125000004432 carbon atom Chemical group C* 0.000 description 26
238000000034 method Methods 0.000 description 21
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 21
125000000217 alkyl group Chemical group 0.000 description 17
102000003946 Prolactin Human genes 0.000 description 14
108010057464 Prolactin Proteins 0.000 description 14
241000700159 Rattus Species 0.000 description 14
229940097325 prolactin Drugs 0.000 description 14
108010036941 Cyclosporins Proteins 0.000 description 12
210000004698 lymphocyte Anatomy 0.000 description 11
238000007920 subcutaneous administration Methods 0.000 description 11
238000012360 testing method Methods 0.000 description 11
208000023275 Autoimmune disease Diseases 0.000 description 10
241000699670 Mus sp. Species 0.000 description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
230000004044 response Effects 0.000 description 10
230000028327 secretion Effects 0.000 description 10
229940126062 Compound A Drugs 0.000 description 9
229930105110 Cyclosporin A Natural products 0.000 description 9
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 9
230000009471 action Effects 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
210000000056 organ Anatomy 0.000 description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
210000000952 spleen Anatomy 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
102000052812 Ornithine decarboxylases Human genes 0.000 description 7
108700005126 Ornithine decarboxylases Proteins 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
210000004989 spleen cell Anatomy 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
231100000155 toxicity by organ Toxicity 0.000 description 7
230000007675 toxicity by organ Effects 0.000 description 7
206010029155 Nephropathy toxic Diseases 0.000 description 6
230000000735 allogeneic effect Effects 0.000 description 6
230000001363 autoimmune Effects 0.000 description 6
231100000417 nephrotoxicity Toxicity 0.000 description 6
230000007694 nephrotoxicity Effects 0.000 description 6
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
206010062016 Immunosuppression Diseases 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
241000282472 Canis lupus familiaris Species 0.000 description 4
208000009386 Experimental Arthritis Diseases 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
239000002775 capsule Substances 0.000 description 4
JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000003550 marker Substances 0.000 description 4
125000004076 pyridyl group Chemical group 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
238000002054 transplantation Methods 0.000 description 4
208000025747 Rheumatic disease Diseases 0.000 description 3
206010052779 Transplant rejections Diseases 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000002585 base Substances 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
230000028993 immune response Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
229960003587 lisuride Drugs 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000005923 long-lasting effect Effects 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
201000004792 malaria Diseases 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
YYPWGCZOLGTTER-MZMPZRCHSA-N pergolide Chemical compound C1=CC=C2[C@H]3C[C@@H](CSC)CN(CCC)[C@@H]3CC3=CN=C1[C]32 YYPWGCZOLGTTER-MZMPZRCHSA-N 0.000 description 3
229960004851 pergolide Drugs 0.000 description 3
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 3
GEUKOOCPPICVTB-SMOCYEBVSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32- Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O GEUKOOCPPICVTB-SMOCYEBVSA-N 0.000 description 2
FCRJELOYDVBTGW-ILZDJORESA-N 3-[(6ar,9s,10ar)-7-propyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea Chemical compound C1=CC([C@H]2C[C@@H](CN([C@@H]2C2)CCC)NC(=O)N(CC)CC)=C3C2=CNC3=C1 FCRJELOYDVBTGW-ILZDJORESA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010019851 Hepatotoxicity Diseases 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241001494479 Pecora Species 0.000 description 2
206010037075 Protozoal infections Diseases 0.000 description 2
BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
102000030621 adenylate cyclase Human genes 0.000 description 2
108060000200 adenylate cyclase Proteins 0.000 description 2
210000001943 adrenal medulla Anatomy 0.000 description 2
239000000556 agonist Substances 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000003904 antiprotozoal agent Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
125000000753 cycloalkyl group Chemical group 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
108010040781 dihydrocyclosporin D Proteins 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000012636 effector Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical group 0.000 description 2
210000005003 heart tissue Anatomy 0.000 description 2
231100000304 hepatotoxicity Toxicity 0.000 description 2
230000007686 hepatotoxicity Effects 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
230000003589 nefrotoxic effect Effects 0.000 description 2
231100000381 nephrotoxic Toxicity 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
229950007140 proterguride Drugs 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
150000003839 salts Chemical group 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000009044 synergistic interaction Effects 0.000 description 2
229960004558 terguride Drugs 0.000 description 2
238000010998 test method Methods 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 1
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
JHWDWUPYEQIICX-HRBVQNPCSA-N (6ar,10ar)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-amine Chemical class C1=CC([C@@H]2[C@H](NCC(C2)N)C2)=C3C2=CNC3=C1 JHWDWUPYEQIICX-HRBVQNPCSA-N 0.000 description 1
DIPBYRMTSXMCIM-MOZMXQSSSA-N (6ar,9r,10ar)-n-[(e,2r,3s)-1,3-dihydroxyoctadec-4-en-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@H](CO)[C@@H](O)/C=C/CCCCCCCCCCCCC)=C3C2=CNC3=C1 DIPBYRMTSXMCIM-MOZMXQSSSA-N 0.000 description 1
KOYMTVWMCXDJNV-UHFFFAOYSA-N 1-[(2-methoxy-6-methylpyridin-3-yl)methyl]aziridine-2-carbonitrile Chemical compound COC1=NC(C)=CC=C1CN1C(C#N)C1 KOYMTVWMCXDJNV-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
238000011749 CBA mouse Methods 0.000 description 1
KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
206010022941 Iridocyclitis Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
JLVHTNZNKOSCNB-YSVLISHTSA-N Mesulergine Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 JLVHTNZNKOSCNB-YSVLISHTSA-N 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
241001529936 Murinae Species 0.000 description 1
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
241000425481 Ocys Species 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
210000004198 anterior pituitary gland Anatomy 0.000 description 1
201000004612 anterior uveitis Diseases 0.000 description 1
230000000884 anti-protozoa Effects 0.000 description 1
230000000842 anti-protozoal effect Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WZJYKHNJTSNBHV-UHFFFAOYSA-N benzo[h]quinoline Chemical class C1=CN=C2C3=CC=CC=C3C=CC2=C1 WZJYKHNJTSNBHV-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
229950006651 bromerguride Drugs 0.000 description 1
150000001649 bromium compounds Chemical class 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
229950003453 ciamexon Drugs 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
238000012136 culture method Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
108010019248 cyclosporin C Proteins 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
229940084985 cyclosporine 100 mg Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229950006629 dosergoside Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000003128 head Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003259 immunoinhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007689 inspection Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
229950008693 mesulergine Drugs 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960004650 metergoline Drugs 0.000 description 1
WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
BOHDKBGWKRCEIT-VQAQLOKVSA-N n-[[(6ar,10ar)-7-methyl-6,6a,8,10a-tetrahydro-4h-indolo[4,3-fg]quinoline-9-yl]methyl]-n-(2-azidoethyl)methanesulfonamide;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=CC([C@H]2C=C(CN(CCN=[N+]=[N-])S(C)(=O)=O)CN([C@@H]2C2)C)=C3C2=CNC3=C1 BOHDKBGWKRCEIT-VQAQLOKVSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000029054 response to nutrient Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NL8700191A 1986-01-31 1987-01-27 Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen. NL8700191A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB868602372A GB8602372D0 (en)	1986-01-31	1986-01-31	Organic compounds
GB8602372		1986-01-31

Publications (1)

Publication Number	Publication Date
NL8700191A true NL8700191A (nl)	1987-08-17

Family

ID=10592282

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8700191A NL8700191A (nl)	1986-01-31	1987-01-27	Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen.

Country Status (14)

Country	Link
EP (1)	EP0231151A3 (da)
JP (1)	JPS62190123A (da)
KR (1)	KR870007126A (da)
AU (1)	AU6812387A (da)
BE (1)	BE1002394A3 (da)
DE (1)	DE3701891A1 (da)
DK (1)	DK47687A (da)
FR (1)	FR2595571A1 (da)
GB (2)	GB8602372D0 (da)
IE (1)	IE870228L (da)
IT (1)	IT1216787B (da)
NL (1)	NL8700191A (da)
SE (1)	SE8700361L (da)
ZA (1)	ZA87712B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8702680A (nl) *	1986-11-21	1988-06-16	Sandoz Ag	Nieuwe benzogchinolinen en werkwijzen voor het bereiden en toepassen van deze verbindingen.
EP0327040A3 (de) *	1988-02-05	1990-11-28	Predrag Dr.Sc. Sikiric	Verwendung von Dopamin und/oder von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung des Verdauungstrakts
CH679277A5 (da) *	1989-02-09	1992-01-31	Sandoz Ag
US5204329A (en) *	1990-06-11	1993-04-20	Du Pont Merck Pharmaceutical Company	Treatment of organ transplantation rejection
DE102005041613A1 (de) *	2005-09-01	2007-03-08	Ergonex Pharma Gmbh	Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3867534A (en) *	1972-08-07	1975-02-18	Upjohn Co	Dosage regimen
US3928612A (en) *	1974-10-02	1975-12-23	American Home Prod	1,2-Dihydro- and 1,2,3,4-tetrahydro-1-oxo-3-isoquinolinecarboxylic acid derivatives as anti-allergic agents
US4225600A (en) *	1977-05-04	1980-09-30	Fisons Limited	Compositions and methods for treating certain skin conditions
CH632161A5 (it) *	1978-01-17	1982-09-30	Siphar Sa	Composizione farmaceutica per il trattamento dell'asma.
DE3247514A1 (de) *	1982-12-20	1984-06-20	Schering AG, 1000 Berlin und 4709 Bergkamen	Zytostatisch wirkende kombination
GB8422253D0 (en) *	1984-09-04	1984-10-10	Sandoz Ltd	Organic compounds

1986
- 1986-01-31 GB GB868602372A patent/GB8602372D0/en active Pending
1987
- 1987-01-23 DE DE19873701891 patent/DE3701891A1/de not_active Withdrawn
- 1987-01-23 EP EP87810040A patent/EP0231151A3/en not_active Withdrawn
- 1987-01-27 NL NL8700191A patent/NL8700191A/nl not_active Application Discontinuation
- 1987-01-28 GB GB08701847A patent/GB2185886A/en not_active Withdrawn
- 1987-01-29 FR FR8701180A patent/FR2595571A1/fr active Pending
- 1987-01-29 DK DK047687A patent/DK47687A/da not_active Application Discontinuation
- 1987-01-29 IE IE870228A patent/IE870228L/xx unknown
- 1987-01-29 AU AU68123/87A patent/AU6812387A/en not_active Abandoned
- 1987-01-30 JP JP62021666A patent/JPS62190123A/ja active Pending
- 1987-01-30 SE SE8700361A patent/SE8700361L/ not_active Application Discontinuation
- 1987-01-30 KR KR870000800A patent/KR870007126A/ko not_active Ceased
- 1987-01-30 IT IT8747586A patent/IT1216787B/it active
- 1987-01-30 BE BE8700066A patent/BE1002394A3/fr active
- 1987-01-30 ZA ZA87712A patent/ZA87712B/xx unknown

Also Published As

Publication number	Publication date
AU6812387A (en)	1987-08-06
DK47687D0 (da)	1987-01-29
DE3701891A1 (de)	1987-08-13
SE8700361L (sv)	1987-08-01
SE8700361D0 (sv)	1987-01-30
BE1002394A3 (fr)	1991-01-29
EP0231151A2 (en)	1987-08-05
IE870228L (en)	1987-07-31
DK47687A (da)	1987-08-01
FR2595571A1 (fr)	1987-09-18
ZA87712B (en)	1988-09-28
IT8747586A0 (it)	1987-01-30
GB2185886A (en)	1987-08-05
GB8701847D0 (en)	1987-03-04
JPS62190123A (ja)	1987-08-20
IT1216787B (it)	1990-03-14
KR870007126A (ko)	1987-08-14
GB8602372D0 (en)	1986-03-05
EP0231151A3 (en)	1990-04-11

Legal Events

Date	Code	Title	Description
1991-09-02	BV	The patent application has lapsed
1993-05-03	BV	The patent application has lapsed

Publication	Publication Date	Title
RU2396982C2 (ru)	2010-08-20	Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов
DE60316798T2 (de)	2008-07-24	Zusammensetzungen und verfahren zur behandlung von diabetes
US5130141A (en)	1992-07-14	Compositions for and methods of treating muscle degeneration and weakness
US20010020036A1 (en)	2001-09-06	5HT1 receptor agonists and metoclopramide for the treatment of migraine
JPH04210915A (ja)	1992-08-03	神経変性疾患用治療剤
LT4516B (lt)	1999-06-25	Rotamazės fermento inhibitoriai
SK161097A3 (en)	1998-11-04	Use of the immunophilin ligand for the preparation of agent to stimulate neuronal growth and regeneration at neuropathological conditions
JPH06508141A (ja)	1994-09-14	新規免疫抑制化合物
TWI250021B (en)	2006-03-01	Pharmaceutical composition for use in the treatment of an inflammatory autoimmune disease or condition
JP2011256195A (ja)	2011-12-22	虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
JP6806685B2 (ja)	2021-01-06	急性放射線症候群を治療するための組成物及び方法
BR112021006033A2 (pt)	2021-09-08	Uso de um inibidor de um transportador da família ent no tratamento de câncer e combinação do mesmo com um antagonista do receptor de adenosina
US6436944B1 (en)	2002-08-20	Combination effective for the treatment of impotence
JP2025027020A (ja)	2025-02-26	患者において血清リン酸塩を低下させるための組み合わせ
JPH04501267A (ja)	1992-03-05	骨髄造血の刺激に有用なヘテロアリール―３―オキソ―プロパンニトリル誘導体
NL8700191A (nl)	1987-08-17	Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen.
AU3724400A (en)	2000-09-28	Methods and compositions for treating erectile dysfunction
US6291509B1 (en)	2001-09-18	Synergistic immunosuppressant composition containing a 2,2'-bi-1H-pyrrole compound
Osterman	1977	A COMPARISON BETWEEN PLACEBO, PIZOTIFEN AND 1‐ISOPROPYL‐3‐HYDROXY‐5‐SEMICARBAZONO‐6‐OXO‐2.3. 5.6.‐TETRAHYDROINDOL (DIVASCAN®) IN MIGRAINE PROPHYLAXIS
JPWO2005007191A1 (ja)	2006-08-31	医薬組成物
Marx	1979	Parkinson's Disease: Search for Better Therapies: More specific drugs, without the adverse side effects of L-dopa, are one of the goals of the research
Bagdy et al.	1987	m-Chlorophenylpiperazine increases blood pressure and heart rate in pithed and conscious rats
JPH05504550A (ja)	1993-07-15	免疫抑制剤として有用なピリミジン生合成インヒビター
CA2167842A1 (en)	1995-02-02	Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes
RU2494738C2 (ru)	2013-10-10	Применение ингибиторов пкс при трансплантации